Symbol="LVTX"
AssetType="Common Stock"
Name="LAVA Therapeutics NV"
Description="Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands."
CIK="1840748"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="YALELAAN 60, UTRECHT, NL"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="42325500"
EBITDA="-39559000"
PERatio="None"
PEGRatio="None"
BookValue="2.43"
DividendPerShare="0"
DividendYield="0"
EPS="-1.54"
RevenuePerShareTTM="0.927"
ProfitMargin="-1.674"
OperatingMarginTTM="-1.654"
ReturnOnAssetsTTM="-0.211"
ReturnOnEquityTTM="-0.514"
RevenueTTM="24264000"
GrossProfitTTM="-20714000"
DilutedEPSTTM="-1.54"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="9.98"
AnalystTargetPrice="6.6"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="5.81"
PriceToBookRatio="1.881"
EVToRevenue="4.935"
EVToEBITDA="-2.619"
Beta="-0.397"
num_52WeekHigh="7.38"
num_52WeekLow="1.365"
num_50DayMovingAverage="1.914"
num_200DayMovingAverage="2.721"
SharesOutstanding="26289100"
DividendDate="None"
ExDividendDate="None"
symbol="LVTX"
open="1.73"
high="1.73"
low="1.64"
price="1.71"
volume="40553.00"
latest_trading_day="2023-08-28"
previous_close="1.65"
change="0.06"
change_percent="3.6364%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="54"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="46"
Volume_recent_avg="431802"
Change_recent_avg="-0.01"
Delta_recent_avg="0.15"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.94"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="46"
Aroon_momentum_negative="54"
image_negative_thumbnail_id_1="150"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0026.jpeg"
image_negative_thumbnail_id_2="134"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_neutral_thumbnail_id_1="542"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0057.jpeg"
image_neutral_thumbnail_id_2="539"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0060.jpeg"
image_positive_thumbnail_id_1="621"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0087.jpeg"
image_positive_thumbnail_id_2="992"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0154.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
